Pre-Open Stock Movers 1/21: (HEB) (YRCW) (DOW) Higher; (AMRN) (PATH) (DB) Lower (more...)

January 21, 2014 9:34 AM EST
Amarin Corporation plc (Nasdaq: AMRN) 23.8% LOWER; announced today that the Division of Metabolism and Endocrinology Products (DMEP) within the U.S. Food and Drug Administration (FDA) has notified Amarin in connection with Amarin's request for reconsideration of DMEP's October 2013 decision to rescind the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement that DMEP "does not plan to re-instate the ANCHOR SPA agreement."

Hemispherx (NYSE: HEB) 21.3% HIGHER; Chardan Capital Markets initiates coverage on Hemispherx with a Buy and $3 price target.

YRC Worldwide Inc. (Nasdaq: YRCW) 17.4% HIGHER; reached a tentative agreement with officials of the International Brotherhood of Teamsters on an extension of its collective bargaining agreement to March 2019.

CytRx (Nasdaq: CYTR) 10.5% HIGHER; announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas. The clinical trial is scheduled to begin this quarter. For purposes of the clinical trial, disease progression is defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion.

NuPathe Inc. (Nasdaq: PATH) 7.5% LOWER; terminated its agreement and plan of merger with Endo Health Solutions Inc. and its Board has withdrawn its recommendation that stockholders accept Endo's offer to acquire all outstanding shares of NuPathe common stock. NuPathe has also entered into an agreement and plan of merger with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) under which Teva will acquire NuPathe for $3.65 per share in cash.

Dow Chemical Co. (NYSE: DOW) 7.7% HIGHER; Activist investor Dan Loeb has taken a large stake in Dow Chemical and he is seeking a spin-off of the company's Petchem business.

BlackBerry (Nasdaq: BBRY) 7.5% HIGHER; According to a recent release from the U.S. Defense Information Systems Agency, about 80,000 BlackBerry devices will work on the U.S. Department of Defense's management system (DoD Mobility Unclassified Capability) at the end of January. About 1,800 devices on Apple (Nasdaq: AAPL) iOS and Google (Nasdaq: GOOG) Android will be supported.

Forest Laboratories, Inc. (NYSE: FRX) 6.1% HIGHER; reported Q3 EPS of $0.07, $0.03 better than the analyst estimate of $0.04. Revenue for the quarter came in at $846.8 million versus the consensus estimate of $827.25 million. Forest Laboratories, Inc. sees FY2014 EPS of $1.25-$1.35, versus the consensus of $1.10.

Inteliquent (NASDAQ: IQNT) 5.5% HIGHER; Raymond James upgraded from Market Perform to Outperform with a price target of $12.00.

Sarepta Therapeutic (NASDAQ: SRPT) 4.6% HIGHER; Needham & Company upgraded from Hold to Buy with a price target of $36 saying share are undervalued even for a conservative regulatory scenario.

Delta Air Lines (NYSE: DAL) 3.9% HIGHER; reported Q4 EPS of $0.65, $0.02 better than the analyst estimate of $0.63. Revenue for the quarter came in at $9.08 billion versus the consensus estimate of $9.03 billion.

Plug Power (NASDAQ: PLUG) 3.7% HIGHER; Cowen initiated coverage with an Outperform rating and price target of $5.00.

Century Aluminum (NASDAQ: CENX) 3.5% HIGHER; JPMorgan upgraded from Underweight to Overweight with a price target of $13.00 (from $6.00).

Alcoa (NYSE: AA) 3.3% HIGHER; JPMorgan upgraded from Neutral to Overweight with a price target of $15.00 (from $9.00).

Gap, Inc. (NYSE: GPS) 3% HIGHER; Sterne Agee initiated coverage with a Buy. PT $44.00.

Denbury Resources Inc. (NYSE: DNR) 3% HIGHER; Barron's positive

SolarCity (NASDAQ: SCTY) 2.7% LOWER; JPMorgan downgraded from Overweight to Neutral with a price target of $68.00 (unchanged).

3D Systems (NYSE: DDD) 2.2% LOWER; Credit Suisse downgraded from Outperform to Neutral.

SanDisk (NASDAQ: SNDK) 2.1% LOWER; BofA/Merrill Lynch downgraded from Neutral to Underperform with a price target of $65 (from $75). Analysts cited weakness in NAND prices and valuation concerns

FireEye, Inc (NASDAQ: FEYE) 2.1% LOWER; JPMorgan downgraded from Overweight to Neutral with a price target of $75.00 (from $64.00).

Deutsche Bank AG (NYSE: DB) 2% LOWER; reports a fourth quarter pretax loss EUR 1.15 billion.

Target (NYSE: TGT) 1.7% LOWER; Cowen downgraded from Market Perform to Underperform with a price target of $47.00 (from $66.00).


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Daniel Loeb, Credit Suisse, Deutsche Bank, JPMorgan, Raymond James, Needham & Company, Third Point LLC, Sterne Agee, Barron's, Cowen & Co, Pre-Open Losers, Pre-Open Winners, Chardan Capital Markets, Definitive Agreement